Macroeconomic PressuresIndustry macroeconomic headwinds have persisted, placing pressure on topline growth for the software segment.
Market SentimentDowngrading Schrödinger to Neutral/High Risk from Buy/High Risk with a new PT of $20, down from $35, reflects reduced market confidence.
Program TerminationDevelopment for SGR-2921 will be discontinued after two clinical trial patient deaths, impacting confidence in the platform.